Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of Cancer.

@article{Liu2016AssessingIA,
  title={Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of Cancer.},
  author={Jing Liu and Stephen James Blake and Heidi Harjunp{\"a}{\"a} and Kirsten A. Fairfax and Michelle C R Yong and Stacey R Allen and Holbrook E. K. Kohrt and Kazuyoshi Takeda and Mark J Smyth and Michele W L Teng},
  journal={Cancer research},
  year={2016},
  volume={76 18},
  pages={5288-301}
}
New combination immunotherapies are displaying both efficacy and immune-related adverse events (irAE) in humans. However, grade 3/4 irAEs occur in a high proportion, which can lead to discontinuation of treatment and can result in fatalities if not promptly treated. Prolonged T regulatory cell (Treg) depletion in tumor-bearing Foxp3-DTR mice using diphtheria toxin (DT) mirrored the spectrum of antitumor responses and severity of irAEs that can occur in ipilimumab/nivolumab-treated patients. In… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 7 times over the past 90 days. VIEW TWEETS